WC
NEPH icon

Wexford Capital’s Nephros NEPH Stock Holding History

Wexford Capital’s Portfolio NEPH Stock Details NEPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.7M Sell
3,600,552
-16,481
-0.5% -$65.8K 1.55% 11
2025
Q4 		$17.7M Hold
3,617,033
– – 3.4% 4
2025
Q3 		$17.1M Buy
3,617,033
+8,952
+0.2% +$35.2K 2.46% 3
2025
Q2 		$14.8M Buy
3,608,081
+7,529
+0.2% +$20.1K 4.12% 3
2025
Q1 		$6.19M Hold
3,600,552
– – 1.61% 13
2024
Q4 		$5.28M Hold
3,600,552
– – 0.84% 18
2024
Q3 		$6.16M Hold
3,600,552
– – 1.47% 14
2024
Q2 		$7.64M Hold
3,600,552
– – 1.93% 9
2024
Q1 		$7.95M Sell
3,600,552
-82,172
-2% -$261K 1.62% 10
2023
Q4 		$12.7M Sell
3,682,724
-4,714
-0.1% -$10.3K 2.73% 3
2023
Q3 		$5.46M Buy
3,687,438
+29,973
+0.8% +$44.6K 1.21% 22
2023
Q2 		$5.67M Hold
3,657,465
– – 1.13% 26
2023
Q1 		$3.91M Hold
3,657,465
– – 0.81% 30
2022
Q4 		$4.24M Hold
3,657,465
– – 0.87% 22
2022
Q3 		$3.33M Buy
3,657,465
+2,354
+0.1% +$3.33K 1.05% 24
2022
Q2 		$175K Sell
3,655,111
-8,858
-0.2% -$23.9K 9.98% 4
2022
Q1 		$534K Buy
3,663,969
+13,440
+0.4% +$63.8K 26.94% 1
2021
Q4 		$647K Buy
+3,650,529
New +$26.7M 26.99% 1
2021
Q2 		$36.9M Buy
3,631,197
+66,667
+2% +$556K 5.55% 3
2021
Q1 		$23.7M Buy
3,564,530
+2,284
+0.1% +$18K 3.54% 3
2020
Q4 		$30.6M Buy
3,562,246
+166,667
+5% +$1.12M 4.79% 3
2020
Q3 		$24.6M Hold
3,395,579
– – 6.57% 2
2020
Q2 		$28.5M Hold
3,395,579
– – 7.16% 1
2020
Q1 		$21.4M Buy
+3,395,579
New +$28.8M 7.91% 1

Other funds holding NEPH

TCM
Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CC
Cornerstone Capital Palo Alto, California $1.12B AUM 28.84% 1-Year Est. Return
BA
Bard Associates Chicago, Illinois $451M AUM 66.6% 1-Year Est. Return
MFIM
Mesirow Financial Investment Management Chicago, Illinois $6.37B AUM 23.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Wexford Capital's NEPH Position: Q1 2026 in Review

Wexford Capital reduced its Nephros (NEPH) stake by 0.46% in Q1 2026, selling an estimated $65.8K and leaving 3,600,552 shares worth $10.7M. The position accounts for 1.55% of the portfolio, ranked #11.

Wexford Capital first reported a position in NEPH in Q1 2020 and has held it in 24 quarters since. The position peaked at $36.9M in Q2 2021. 27 funds tracked by Wall St. Rank hold NEPH as of Q1 2026.

  • Wexford Capital held 3,600,552 shares of Nephros worth $10.7M as of Q1 2026.
  • Wexford Capital sold 16,481 Nephros shares in Q1 2026, an estimated $65.8K.
  • Nephros made up 1.55% of Wexford Capital's portfolio in Q1 2026, its #11 holding.
  • Wexford Capital first reported a position in Nephros in Q1 2020 and has held it in 24 quarters since.
  • Wexford Capital's Nephros position peaked at $36.9M in Q2 2021.
  • 27 funds tracked by Wall St. Rank held Nephros as of Q1 2026.

Based on Wexford Capital's 13F filing for Q1 2026, filed 15 May 2026.